Multiple joint effusions associated with high-dose imatinib therapy in a patient with chronic myelogenous leukaemia.
Multiple joint effusions associated with high-dose imatinib therapy in a patient with chronic myelogenous leukaemia.
复制标题
慢性粒细胞白血病患者与高剂量伊马替尼治疗相关的多发性关节积液。
DOI：
10.1111/j.1600-0609.2006.00649.x
复制
发表时间：
2006
期刊：
影响因子：
--
通讯作者：
TiongOng,S
中科院分区：
文献类型：
--
作者：
Moore,JamesC;Dennehey,CarolynF;Anavim,Arash;Kong,KevinM;TiongOng,S
翻译后摘要：甲磺酸伊马替尼是一种小分子酪氨酸激酶抑制剂，在慢性粒细胞白血病（CML）的治疗具有显着的疗效。然而，CML患者可能需要长期甚至终身治疗。一般而言，伊马替尼治疗的副作用为轻度至中度，绝大多数患者可耐受长期治疗。然而，少数患者对治疗完全不耐受，而其他患者尽管有显著的副作用，仍能够继续治疗。在这里，我们描述了一种新形式的液体潴留，表现为高剂量伊马替尼治疗的晚期CML患者的多关节积液，以及为控制这种不良事件而采取的成功措施。尽管之前已经描述了液体潴留，包括眶周水肿、胸腔积液和心包积液以及危及生命的脑水肿，并将其归因于伊马替尼，但这是我们发现的首例伊马替尼相关多关节积液。需要进一步的工作来证实伊马替尼治疗和这种新的副作用之间的因果关系，以及确定潜在的病理生理机制。
Abstract:Imatinib mesylate is a small molecule tyrosine kinase inhibitor that has significant efficacy in the treatment of chronic myelogenous leukaemia (CML). However, it is likely that patients with CML will require prolonged and perhaps life‐long therapy. In general, the side‐effects of imatinib therapy have been mild to moderate, with the large majority of patients tolerating prolonged periods of therapy. However, a minority of patients are completely intolerant of therapy, while others are able to remain on therapy despite significant side‐effects. Here, we describe a novel form of fluid retention presenting as multiple joint effusions in a patient with advanced phase CML on high‐dose imatinib, as well as successful measures that were undertaken to control this adverse event. Although fluid retention, including periorbital oedema, pleural and pericardial effusions, as well as life‐threatening cerebral oedema have been previously described and attributed to imatinib, this is the first case of imatinib‐associated polyarticular effusions that we are aware of. Further work will be required to confirm a casual relationship between imatinib therapy and this novel side‐effect, as well as to determine the underlying pathophysiologic mechanisms.